Skip to content
Screener

TG Therapeutics TGTX Q2 2026 earnings

Reported August 3, 2026 · Before market open

Revenue$240.3MBeat by $10.6M
EPS$0.05Miss by $0.26
Revenue estimate$229.8M
EPS estimate$0.31
“The second quarter of 2026 was another strong quarter for TG Therapeutics. BRIUMVI delivered another outstanding commercial quarter, exceeding our expectations once again and putting us on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate. Mr. Weiss continued”
Michael S. Weiss

Next report

Nov 2, 2026 (in a month)
Revenue estimate$245.2M
EPS estimate$0.36

Financials

Q2 2026

Income statement

See full
Revenue$240.3M+70.3%
Gross profit$199.1M+62.9%
Operating income$21.7M-37.8%
Net income$7.8M-72.4%
EPS (diluted)$0.05-70.6%

Balance sheet

See full
Cash & equivalents$482.6M+274%
Total debt$754.4M+197%
Total equity$604.1M+119%
Total assets$1.6B+133%

Cash flow

See full
Operating cash flow$39.3M—
CapEx$293.0K+598%
Free cash flow$39.0M—

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$8.21B+41.1%
Enterprise value$8.48B+41.4%
P/E18.6×+5.6×
P/S10.3×-0.7×

Profitability

See full
Gross margin82.4%-4.6pp
Operating margin17.1%-1.9pp
Net margin55.2%+41.9pp

Returns & leverage

See full
Return on equity100.3%+73.6pp
Debt / equity1.2×+0.3×
Current ratio4.3×+0.4×

FAQ

When did TG Therapeutics report Q2 2026 earnings?
TG Therapeutics (TGTX) reported Q2 2026 earnings on August 3, 2026 before market open.
What were TG Therapeutics's Q2 2026 revenue and EPS?
TG Therapeutics reported revenue of $240.3M and eps of $0.05 for Q2 2026.
Did TG Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $229.8M by $10.6M. EPS missed the consensus estimate of $0.31 by $0.26.
How did TG Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 70.3% from $141.1M a year earlier and eps declined 70.6% from $0.17.
Where can I find TG Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-025304) and the 10-Q periodic report (0001437749-26-025955) directly on SEC EDGAR. The filing index links above go to sec.gov.